- Home
- CHPT vs STOK Comparison
CHPT vs STOK Comparison
Compare CHPT & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPT
- STOK
- Stock Information
- Founded
- CHPT 2007
- STOK 2014
- Country
- CHPT United States
- STOK United States
- Employees
- CHPT N/A
- STOK N/A
- Industry
- CHPT Industrial Specialties
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- CHPT Consumer Discretionary
- STOK Health Care
- Exchange
- CHPT Nasdaq
- STOK Nasdaq
- Market Cap
- CHPT 468.9M
- STOK 556.7M
- IPO Year
- CHPT N/A
- STOK 2019
- Fundamental
- Price
- CHPT $0.61
- STOK $6.67
- Analyst Decision
- CHPT Hold
- STOK Strong Buy
- Analyst Count
- CHPT 10
- STOK 8
- Target Price
- CHPT $1.69
- STOK $23.83
- AVG Volume (30 Days)
- CHPT 22.8M
- STOK 859.6K
- Earning Date
- CHPT 03-04-2025
- STOK 03-18-2025
- Dividend Yield
- CHPT N/A
- STOK N/A
- EPS Growth
- CHPT N/A
- STOK N/A
- EPS
- CHPT N/A
- STOK N/A
- Revenue
- CHPT $417,083,000.00
- STOK $36,555,000.00
- Revenue This Year
- CHPT $14.08
- STOK N/A
- Revenue Next Year
- CHPT $26.64
- STOK N/A
- P/E Ratio
- CHPT N/A
- STOK N/A
- Revenue Growth
- CHPT N/A
- STOK 316.34
- 52 Week Low
- CHPT $0.56
- STOK $6.60
- 52 Week High
- CHPT $2.44
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- CHPT 35.90
- STOK 30.56
- Support Level
- CHPT $0.66
- STOK $7.18
- Resistance Level
- CHPT $0.71
- STOK $8.45
- Average True Range (ATR)
- CHPT 0.05
- STOK 0.58
- MACD
- CHPT 0.00
- STOK -0.08
- Stochastic Oscillator
- CHPT 22.64
- STOK 1.07
About CHPT ChargePoint Holdings Inc.
ChargePoint designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.